Location Cherry Hill, New Jersey, United States Regions Greater Philadelphia Area, East Coast, Northeastern US Gender Male
LinkedIn View on LinkedIn
Howard Pien has worked in the pharmaceutical and biotechnology industries for over 30 years. From 2007 to 2009, he was the Chairman and CEO of MedareX, a public biotechnology company, until it was acquired by BMS. From 2003 to 2006, he was the Chairman and CEO of Chiron, a public biotechnology company, which was acquired by Novartis.
Between
1991 and 2003, he held various positions in GlaxoSmithKline, a multinational pharmaceutical company, and its predecessor, Smith Kline Beecham, as head of New Product Development, head of US Marketing, head of North Asia, head of UK, head of US, head of International, and as head of Worldwide Pharmaceuticals Operations.
Prior to GSK, Howard worked for AbbottLabs for siX years and Merck & Co., Inc. for five years, in Various marketing and sales positions. He currently serves as a Director on the Boards of Viropharma (as Lead Independent Director), Vanda (as Non-Executive Chairman), lmmunogen, and Talon, all public biotechnology companies, and lkaria, a privately-held specialty pharmaceutical company.
He is also an advisor to the Life Sciences Practice of Warburg Pincus, a private equity firm. Previously, Howard served on various non-profit boards, including the industry associations BIO and PhRMA, as well as Oakland Children’s Hospital and Fox Chase Hospital. He graduated from MIT with a BS in civil engineering, and from Carnegie-Mellon University with an MBA. His principal residence is in Cherry Hill, NJ.
